BR9404842A - Compostos,processo para sua preparação e formulação farmacêutica - Google Patents

Compostos,processo para sua preparação e formulação farmacêutica

Info

Publication number
BR9404842A
BR9404842A BR9404842A BR9404842A BR9404842A BR 9404842 A BR9404842 A BR 9404842A BR 9404842 A BR9404842 A BR 9404842A BR 9404842 A BR9404842 A BR 9404842A BR 9404842 A BR9404842 A BR 9404842A
Authority
BR
Brazil
Prior art keywords
compounds
preparation
pharmaceutical formulation
trisubstituted
piperidinyl
Prior art date
Application number
BR9404842A
Other languages
English (en)
Inventor
Scott Alan Frank
Douglas Edward Prather
Jeffrey Alan Ward
John Arnold Werner
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9404842A publication Critical patent/BR9404842A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR9404842A 1993-12-08 1994-12-02 Compostos,processo para sua preparação e formulação farmacêutica BR9404842A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/164,074 US5434171A (en) 1993-12-08 1993-12-08 Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates

Publications (1)

Publication Number Publication Date
BR9404842A true BR9404842A (pt) 1995-08-08

Family

ID=22592858

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9404842A BR9404842A (pt) 1993-12-08 1994-12-02 Compostos,processo para sua preparação e formulação farmacêutica

Country Status (31)

Country Link
US (1) US5434171A (pt)
EP (3) EP0984004A3 (pt)
JP (2) JP3834075B2 (pt)
KR (1) KR100356239B1 (pt)
CN (2) CN1057294C (pt)
AT (1) ATE200279T1 (pt)
AU (1) AU681198B2 (pt)
BR (1) BR9404842A (pt)
CA (1) CA2137221C (pt)
CO (1) CO4290427A1 (pt)
CZ (1) CZ290559B6 (pt)
DE (1) DE69427017T2 (pt)
DK (1) DK0657428T3 (pt)
ES (1) ES2155844T3 (pt)
FI (2) FI106455B (pt)
GR (1) GR3036136T3 (pt)
HK (1) HK1013826A1 (pt)
HU (1) HUT71489A (pt)
IL (1) IL111843A (pt)
MY (1) MY121543A (pt)
NO (1) NO302884B1 (pt)
NZ (1) NZ270039A (pt)
PE (1) PE41495A1 (pt)
PL (1) PL181734B1 (pt)
PT (1) PT657428E (pt)
RU (1) RU2145958C1 (pt)
SI (1) SI0657428T1 (pt)
TW (1) TW290540B (pt)
UA (1) UA52577C2 (pt)
YU (2) YU82304A (pt)
ZA (1) ZA949584B (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722497B1 (fr) * 1994-07-13 1996-08-14 Synthelabo Esters de alpha-4-chlorophenyl)-4-(4-fluorophenyl)methyl) piperidine-1-ethanol, leur preparation et leur application en therapeutique
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
CA2449175A1 (en) * 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
US20030068829A1 (en) * 2001-06-25 2003-04-10 Symyx Technologies, Inc. High throughput crystallographic screening of materials
AU2002360284B2 (en) * 2001-10-18 2006-11-02 Nektar Therapeutics Polymer conjugates of opioid antagonists
US6794510B2 (en) * 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
US20050004155A1 (en) * 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
US20050148630A1 (en) * 2003-12-02 2005-07-07 Carpenter Randall L. Methods of preventing and treating non-opioid induced gastrointestinal dysfunction
US8946262B2 (en) * 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
CA2758460C (en) * 2003-12-16 2014-09-23 Nektar Therapeutics Methods of preparing monodisperse oligo (ethylene glycol) reagent compositions
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
US20050240177A1 (en) * 2004-04-26 2005-10-27 Packaging Service Corporation Of Kentucky Electrosurgical forceps
US7700626B2 (en) 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
AU2005272598B2 (en) * 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US20060211733A1 (en) * 2005-03-04 2006-09-21 Adolor Corporation Methods of preventing and treating opioid bowel dysfunction
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CA2600350C (en) * 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
CN101262867A (zh) * 2005-07-01 2008-09-10 叶林发现公司 用于治疗肥胖的mao-b抑制剂
US7914776B2 (en) * 2005-10-07 2011-03-29 Adolor Corporation Solid dispersions of opioid antagonists
US20070092576A1 (en) * 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
CN100383121C (zh) * 2006-03-07 2008-04-23 天津泰普药品科技发展有限公司 阿韦苄酯化合物及其制备方法和以该化合物制备阿韦莫哌的工艺
EP2034977B1 (en) 2006-04-21 2011-07-13 DSM IP Assets B.V. Use of opioid receptor antagonists
EP2101773A2 (en) * 2006-11-22 2009-09-23 Progenics Pharmaceuticals, Inc. (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
ES2765811T5 (es) 2007-03-29 2024-02-27 Progenics Pharm Inc Forma cristalina de bromuro de (R)-n-metilnaltrexona y sus usos
EP3064503A1 (en) 2007-03-29 2016-09-07 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
PT2565195E (pt) 2007-03-29 2015-07-28 Wyeth Llc Antagonistas e receptor opióide periférico e respectivas utilizações
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009117669A2 (en) 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
EP2331140B1 (en) 2008-08-11 2018-07-04 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN101429154B (zh) * 2008-11-14 2011-01-05 天津泰普药品科技发展有限公司 无水阿维莫泮及其药物组合物
US20100311782A1 (en) 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
AU2010326676B2 (en) 2009-12-04 2013-03-14 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose
WO2011161646A2 (en) 2010-06-25 2011-12-29 Ranbaxy Laboratories Limited Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
CN103360302B (zh) * 2012-03-29 2015-08-26 北大方正集团有限公司 阿维莫泮的纯化方法
WO2016064914A1 (en) 2014-10-20 2016-04-28 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
JP2018534269A (ja) 2015-10-01 2018-11-22 エリージウム セラピューティクス, インコーポレイテッド 過剰摂取および乱用に抵抗性のポリサブユニットオピオイドプロドラッグ
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
WO2018170465A1 (en) 2017-03-17 2018-09-20 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136040A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Preparation of substituted tetrahydropyridines
CZ284993B6 (cs) * 1991-03-29 1999-04-14 Eli Lilly And Company Derivát piperidinu
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists

Also Published As

Publication number Publication date
CN1223257A (zh) 1999-07-21
YU49312B (sh) 2005-06-10
UA52577C2 (uk) 2003-01-15
RU94042903A (ru) 1996-10-27
CN1121387C (zh) 2003-09-17
HUT71489A (en) 1995-11-28
CA2137221C (en) 2011-02-22
FI945703A0 (fi) 1994-12-02
CN1057294C (zh) 2000-10-11
GR3036136T3 (en) 2001-09-28
PT657428E (pt) 2001-07-31
ATE200279T1 (de) 2001-04-15
FI106860B (fi) 2001-04-30
HU9403466D0 (en) 1995-02-28
YU82304A (sh) 2006-03-03
RU2145958C1 (ru) 2000-02-27
NO302884B1 (no) 1998-05-04
JP3834075B2 (ja) 2006-10-18
KR100356239B1 (ko) 2002-12-26
FI945703A (fi) 1995-06-09
DK0657428T3 (da) 2001-05-07
PL181734B1 (pl) 2001-09-28
NO944644D0 (no) 1994-12-02
TW290540B (pt) 1996-11-11
AU7917094A (en) 1995-06-15
EP1607387A3 (en) 2007-01-03
HK1013826A1 (en) 1999-09-10
CA2137221A1 (en) 1995-06-09
EP0657428B1 (en) 2001-04-04
YU70294A (sh) 1997-07-31
CZ299294A3 (en) 1995-10-18
IL111843A0 (en) 1995-03-15
PE41495A1 (es) 1995-11-28
DE69427017D1 (de) 2001-05-10
CZ290559B6 (cs) 2002-08-14
EP1607387A2 (en) 2005-12-21
KR950017957A (ko) 1995-07-22
CN1111239A (zh) 1995-11-08
JP2006070042A (ja) 2006-03-16
DE69427017T2 (de) 2001-09-06
NO944644L (no) 1995-06-09
MY121543A (en) 2006-02-28
CO4290427A1 (es) 1996-04-17
EP0984004A2 (en) 2000-03-08
ES2155844T3 (es) 2001-06-01
EP0657428A1 (en) 1995-06-14
NZ270039A (en) 1996-08-27
FI106455B (fi) 2001-02-15
PL306068A1 (en) 1995-06-12
ZA949584B (en) 1996-06-03
IL111843A (en) 2000-02-29
US5434171A (en) 1995-07-18
FI20000353A (fi) 2000-02-17
EP0984004A3 (en) 2003-10-15
JPH07215937A (ja) 1995-08-15
SI0657428T1 (en) 2001-08-31
AU681198B2 (en) 1997-08-21

Similar Documents

Publication Publication Date Title
BR9404842A (pt) Compostos,processo para sua preparação e formulação farmacêutica
BR9201084A (pt) Composto,formulacao farmaceutica e processo para a sua preparacao do composto
BR8701750A (pt) Derivado de 2-fenoxipirimidina,composicao herbicida,processo para exterminar ervas daninhas,e processo para a producao de um derivado de 2-fenoxipirimidina
BR8606430A (pt) Derivado de oxima de pirazol,processo para sua producao e composicao inseticida e acaricida
BR9400616A (pt) Processo para a preparação de 1,1,1,4,4,4-hexafluorbuteno-2
PT101169A (pt) Processo para a preparacao de 4,5-di-hidrogeldanamicina e sua hidroquinona, hidroquinona obtida e composicao contendo um destes compostos
BR8906576A (pt) Processo para a preparacao de um derivado de pirimidina,mistura herbicida e composicao herbicida
BR8806217A (pt) Derivados de 2,2-difluorciclopropiletano,processo para sua preparacao,composicoes praguicidas e aplicacao
BR9404776A (pt) Processo para a preparação de 2,2-difluorceteno silil acetais e processo para a preparação de ésteres de ácido alfa,alfa-diflúor-beta-sililóxi-1,3-dioxolano-4-propanóico
BR9400604A (pt) Processo para a preparação de 1,1,1,3,3-pentafluorpropano
ES2070109T3 (es) Sales diaminicas de acido clavulanico.
BR9205413A (pt) Processo para a preparação de (S)-cianoidrinas oticamente ativas.
ITMI910284A0 (it) Processo per la preparazione di 2,2,6,6-tetrametil-4-piperidilammine
ITMI910320A0 (it) Processo per la preaparazione di 1.3-diossoli
EG18555A (en) Process for preparing a substituted benzamides as anticonvulsant agents
BR8801838A (pt) N-arilpirrolin-2,5-dionas,processo para sua preparacao,composicoes herbicidas,processo para combater ervas daninhas e para a preparacao de composicoes,derivados e compostos
BR8804931A (pt) Processo para a producao de uma tetra-hidro-1,3,5-tiadiazin-4-ona,e,composicao inseticida
PT96088A (pt) Processo para a preparacao de compostos moluscicidas 2,4,5-tribomopirrole-3-carbonitrilo
BR9202993A (pt) Composto a87689,processo para sua preparacao,cultura e formulacao farmaceutica
BR1100399A (pt) Composto, formulação farmacêutica, uso de 5-etiniluracila, e, processo para preparar uma formulação.
BR9001866A (pt) Composicoes praguicidas,processo para a preparacao de compostos e utilizacao
BR1100797A (pt) Composto, composição farmacêutica, utilização de um composto, e, processo para a preparação de um composto
ITMI922141A1 (it) 5-nitro-metil-imidazolil-3-terbutil-2-idrossiaril-carbinoli, un processo per la loro preparazione e relative composizioni terapeutiche.
BR9302642A (pt) Compostos,processo para sua preparacao,medicamento e uso
BR8900533A (pt) Composto de benzoxazinona,processo para sua preparacao,e composicao herbicida

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
CKFC Appeal: appeal against refusal